• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    AMYRIS SUCCESSFULLY LAUNCHES TWO NEW CONSUMER BRANDS

    10/24/22 8:00:00 AM ET
    $AMRS
    Major Chemicals
    Industrials
    Get the next $AMRS alert in real time by email

    EMERYVILLE, Calif., Oct. 24, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, announces the launch of two new brands under its growing consumer portfolio: Stripes™, a (peri)menopausal wellness brand founded in partnership with actress, entrepreneur and activist, Naomi Watts, and EcoFabulous™, a clean, sustainable beauty brand designed for Gen-Z consumers, offering high performing color cosmetics and skin-care products at an accessible price point.

    Amyris Logo (PRNewsfoto/Amyris, Inc.)

    Stripes officially launched last week Tuesday, October 18, on World Menopause Day with the products available at iamstripes.com. EcoFabulous launched last week Thursday, October 20, and is available at ecofabulous.com. Both brands will be available on Amazon in November. Amyris will soon be announcing the launch of both brands into some of the leading physical retail stores.

    With these launches, Amyris continues to expand its trusted, science-backed, clean brand portfolio, which includes leading consumer brands in the hair, beauty, skincare, baby care and color cosmetics categories such as Biossance®, JVN™, Rose Inc.™, Pipette and Costa Brazil®.

    "We are very pleased with the early success of these brands as they join our award-winning consumer brand portfolio delivering the best of clean, sustainable beauty powered by our Lab-to-Market technology platform," said John Melo, President and Chief Executive Officer. "We continue to experience very strong consumer demand for our brands across each of our categories and expect an excellent finish to 2022."

    About Amyris

    Amyris (NASDAQ:AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market™ technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit www.amyris.com.

    Amyris, the Amyris logo, Biossance, Costa Brazil, JVN, Lab-to-Market, Pipette, and Rose Inc. are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the U.S. and/or other countries.

    Forward-Looking Statements 

    This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding Amyris' expectations regarding launch of Stripes and EcoFabulous in physical retail stores and the timing thereof, consumer demand for its products, and financial performance in the remainder of 2022. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris' liquidity and ability to fund operating and capital expenses, risks related to its financing activities, risks related to potential delays or failures in completing and integrating planned acquisitions, risks related to potential delays or failures in development, regulatory approval, launch, production and commercialization of products, risks related to the COVID-19 pandemic and any other geopolitical events, including Russia's invasion of Ukraine, resulting in global economic, financial and supply chain disruptions that may negatively impact Amyris' business operations and financial results or cause market volatility, risks related to Amyris' reliance on third parties particularly in the supply chain, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise. 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-successfully-launches-two-new-consumer-brands-301656997.html

    SOURCE Amyris, Inc.

    Get the next $AMRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRS

    DatePrice TargetRatingAnalyst
    5/18/2023$3.10 → $0.65Buy → Hold
    Jefferies
    5/10/2023$4.00 → $1.25Outperform → Market Perform
    TD Cowen
    4/28/2023$1.50Buy
    Canaccord Genuity
    11/10/2022Overweight → Neutral
    JP Morgan
    11/9/2022Outperform → Perform
    Oppenheimer
    8/10/2022$4.00 → $2.00Buy → Neutral
    ROTH Capital
    6/24/2022Neutral
    JP Morgan
    5/25/2022$2.50Neutral
    Piper Sandler
    More analyst ratings